AI Article Synopsis
- - The study aimed to find how often Her-2 overexpression occurs in patients with poorly differentiated carcinoma or adenocarcinoma of unknown origin.
- - Out of 100 tumor specimens analyzed, 94 were successfully stained for Her-2, revealing that 11% of these (10 patients) showed Her-2 overexpression, primarily in cases of poorly differentiated adenocarcinoma.
- - The findings suggest that Her-2 overexpression is rare in these patients, and further research is needed to assess its prevalence in adenocarcinomas of unknown primary site, along with potential treatments like trastuzumab.
Article Abstract
Purpose: To determine the frequency of Her-2 overexpression in patients with poorly differentiated carcinoma or poorly differentiated adenocarcinoma of unknown primary site.
Patients And Methods: Tumor specimens from 100 patients with poorly differentiated carcinoma or poorly differentiated adenocarcinoma were stained for the Her-2 protein using the Dako immunohistochemical method. Clinical and pathologic characteristics of patients with and without Her-2 overexpression were compared.
Results: Staining for Her-2 overexpression was successful in 94 of 100 patients. Ten (11%) of 94 tumor specimens overexpressed Her-2. Eight of 10 overexpressors had poorly differentiated adenocarcinoma, and all overexpressors had predominant tumor location above the diaphragm, usually in the mediastinum or lungs.
Conclusion: Her-2 overexpression occurs in a minority of patients with poorly differentiated carcinoma/adenocarcinoma of unknown primary site. Because most overexpressors had poorly differentiated adenocarcinoma, further evaluation of patients with adenocarcinoma of unknown primary site is necessary to determine the frequency of Her-2 overexpression in this common subgroup. Evaluation of the efficacy of trastuzumab in Her-2 overexpressors with carcinoma of unknown primary site is indicated.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1200/JCO.2000.18.3.632 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
EpigenPlot: An interactive web platform for DNA methylation-based biomarker and drug target discovery in colorectal cancer.
Br J Pharmacol
January 2025
Department of Bioinformatics, Semmelweis University, Budapest, Hungary.
Background And Purpose: Genome-wide methylation studies have significantly advanced our understanding of colorectal adenocarcinoma progression and biomarker discovery. Aberrant DNA methylation plays a crucial role in gene expression regulation during cancer transformation, highlighting the need to identify differentially methylated regions (DMRs) as potential diagnostic and therapeutic markers. However, an integrated resource to explore and validate methylation alterations across colorectal cancer stages has been lacking.
View Article and Find Full Text PDFS100A13-driven interaction between pancreatic adenocarcinoma cells and cancer-associated fibroblasts promotes tumor progression through calcium signaling.
Cell Commun Signal
January 2025
School of Pharmacy, Naval Medical University, Shanghai, 200433, China.
Background: Cancer-associated fibroblasts (CAFs) are key components of the pancreatic adenocarcinoma (PAAD) tumor microenvironment (TME), where they promote tumor progression and metastasis through immunosuppressive functions. Although significant progress has been made in understanding the crosstalk between cancer cells and CAFs, many underlying mechanisms remain unclear. Recent studies have highlighted the importance of calcium signaling in enhancing interactions between tumor cells and the surrounding stroma, with the S100 family of proteins serving as important regulators.
View Article and Find Full Text PDFEffect of KRAS mutation status on clinicopathological characteristics and overall survival in patients with rectal cancer.
BMC Gastroenterol
January 2025
Department of Gastrointestinal Surgery, Fujian Medical University Provincial Clinical College FuZhou FuJiang, Fuzhou, China.
Background: KRAS mutations in rectal cancer are associated with a conflict prognosis. This study aimed to compare clinicopathological outcomes of patients and tumor criteria between wKRAS and mKRAS, as well as overall survival in the two groups.
Methods: The research retrospectively analyzed a cohort of 193 patients who received surgical treatment for rectal adenocarcinoma between May 2015 and December 2023.
Patterns, timing and predictors of recurrence following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: an international multicentre retrospective cohort study.
HPB (Oxford)
December 2024
University Hospitals Plymouth NHS Trust, Plymouth, United Kingdom. Electronic address:
Background: Most patients undergoing pancreaticoduodenectomy (PD) for pancreatic ductal adenocarcinoma (PDAC) develop recurrence. No previous studies have investigated predictors of local-only recurrence following PD for PDAC. Our study aimed to determine timing, pattern and predictors of any-site and local-only recurrence following PD for PDAC.
View Article and Find Full Text PDFComparative impact of tertiary lymphoid structures and tumor-infiltrating lymphocytes in cholangiocarcinoma.
J Immunother Cancer
January 2025
Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan
Background: Cholangiocarcinoma is a challenging malignancy with limited responses to conventional therapies, particularly immune checkpoint inhibitor therapy. Tumor-infiltrating lymphocytes (TILs) and tertiary lymphoid structures (TLSs) are key components of the tumor microenvironment (TME) and have been implicated in the immune response to cancer. However, the role and difference of TLSs and TILs in patients with cholangiocarcinoma remains unclear.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!